Background : The L-dopa inhaler CVT-301 is presently being assessed for its use in
Parkinson’s Disease. It is designed to deliver a precise dose of a dry powder formulation of
L-dopa. Inhaled L-dopa enters the body through the lungs and then reaches the brain far more
quickly by bypassing the digestive system.
For more information go to : http://www.acorda.com/products/research-development/cvt-301
Methods : Patients used the L-dopa inhaler CVT-301 up to 3
times per day for OFF episodes. After 2 weeks, the
study-drug dose was increased from 35mg to 50 mg. The
patients were assessed after 10, 20, 30, and 60 minutes.
Results: The L-dopa inhaler was used at an average of 2.1
times per day. The UPDRS Part III score (Parkinson’s
Disease symptoms) clearly improved. A treatment effect was
already evident after only 10 minutes.
Adverse effects : The most frequently reported adverse events in those using CVT-301 were
dizziness, cough, and nausea, each in 7% of patients.
Conclusion : As the effect was already seen after 10 minutes, which is the shortest time
assessed, the effect could be even quicker. Consequently, CVT-301 could become of
widespread use in Parkinson’s Disease for when a quick effect is needed.
Reference : Movement Disorders [2016] 31 (9) : 1356-1365 (P.A.LeWitt, R.A.Hauser, D.G.
Grosset, F.Stocchi, M.H.Saint-Hilaire, A.Ellenbogen, M.Leinonen, N.B.Hampson, T.DeFeo-
Fraulini, M.I.Freed, K.D.Kieburtz)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27090868
http://www.viartis.net/parkinsons.disease/news/180106.pdf
No comments:
Post a Comment